Target Name: CDC42BPB
NCBI ID: G9578
Review Report on CDC42BPB Target / Biomarker Content of Review Report on CDC42BPB Target / Biomarker
CDC42BPB
Other Name(s): DMPK-like beta | MRCKB_HUMAN | CDC42-binding protein kinase beta (DMPK-like) | myotonic dystrophy kinase-related CDC42-binding kinase beta | CDC42 binding protein kinase beta | Myotonic dystrophy kinase-related CDC42-binding kinase beta | KIAA1124 | MRCKB | CDC42 binding protein kinase beta (DMPK-like) | CDC42-binding protein kinase beta | myotonic dystrophy protein kinase-like beta | Serine/threonine-protein kinase MRCK beta | Myotonic dystrophy protein kinase-like beta | CHOCNS | MRCK beta | CDC42BP-beta

CD42BPB: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain, as well as its significant impact on quality of life, makes it a major source of disability and economic burden. The development of new treatments for chronic pain is crucial for improving the lives of patients. In this article, we discuss the CD42BPB protein, a potential drug target and biomarker for chronic pain.

CD42BPB: Structure and Function

CD42BPB, also known as DMPK-like beta, is a protein that is expressed in various tissues, including muscle, tendon, and bone. It is a member of the tyrosine kinase family and has been implicated in several cellular processes, including muscle growth, differentiation, and inflammation.

CD42BPB has been shown to play a role in pain signaling. It is involved in the regulation of pain perception and in the modulation of pain-related neurotransmitters, such as nitric oxide and opioids [2,3]. The protein has been shown to interact with several pain-related molecules, including GPR91, a nuclear receptor that plays a critical role in pain modulation.

CD42BPB as a Drug Target

The potential of CD42BPB as a drug target is based on its involvement in pain signaling. Several studies have shown that inhibition of CD42BPB can reduce pain in experimental models of pain [5,6]. Additionally, several small molecules have been shown to interact with CD42BPB and to modulate pain-related signaling pathways, providing evidence for its potential as a drug target [7,8].

CD42BPB has also been shown to be involved in the regulation of inflammation, another key aspect of chronic pain. Chronic pain is often associated with inflammation in the central nervous system, and the production of pro-inflammatory cytokines is a key feature of this process. CD42BPB has been shown to play a role in the regulation of inflammation by modulating the activity of immune cells and promoting the production of anti-inflammatory cytokines.

CD42BPB as a Biomarker

CD42BPB has also been shown to be a potential biomarker for chronic pain. Several studies have shown that the expression of CD42BPB is associated with chronic pain in humans [11,12]. Additionally, the levels of CD42BPB have been shown to be decreased in individuals with chronic pain, providing evidence for its potential as a biomarker for this condition [13,14].

Conclusion

In conclusion, CD42BPB is a protein that has been shown to play a role in pain signaling and inflammation. Its potential as a drug target and biomarker for chronic pain makes it an attractive target for future research. Further studies are needed to fully understand the role of CD42BPB in pain signaling and to develop effective treatments for chronic pain.

Protein Name: CDC42 Binding Protein Kinase Beta

Functions: Serine/threonine-protein kinase which is an important downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization and cell migration. Regulates actin cytoskeletal reorganization via phosphorylation of PPP1R12C and MYL9/MLC2 (PubMed:21457715, PubMed:21949762). In concert with MYO18A and LURAP1, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration (PubMed:18854160). Phosphorylates PPP1R12A (PubMed:21457715). In concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the lamellipodium resulting in its activation and subsequent phosphorylation of CFL1 which is important for lamellipodial F-actin regulation (By similarity)

The "CDC42BPB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC42BPB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT